Thank you for standing by. My name is Amy, and I will be your operator for today. At this time, I would like to welcome everyone to the AtaiBeckley EMP-01 Phase IIa Topline Data Conference Call.
However, an exploratory analysis of a pre-specified subgroup of patients with TP53 wild-type endometrial cancer showed a promising efficacy signal. In the SIENDO study, 263 patients were randomly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results